Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Carolyn Ruth Bertozzi is an American chemist and Nobel laureate, known for her wide-ranging work spanning both chemistry and biology. She coined the term "bioorthogonal chemistry" for chemical reactions compatible with living systems. Her recent efforts include synthesis of chemical tools to study cell surface sugars called glycans and how they affect diseases such as cancer, inflammation, and viral infections like COVID-19. At Stanford University, she holds the Anne T. and Robert M. Bass Professorship in the School of Humanities and Sciences. Bertozzi is also an Investigator at the Howard Hughes Medical Institute (HHMI) and is the former director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory.
Thermo Fisher Scientific Inc. is an American-headquartered life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).
Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.
The California Institute for Quantitative Biosciences (QB3) is a nonprofit research and technology commercialization institute affiliated with three University of California campuses in the San Francisco Bay Area: Berkeley, San Francisco, and Santa Cruz. QB3's domain is the quantitative biosciences: areas of biology in which advances are chiefly made by scientists applying techniques from physics, chemistry, engineering, and computer science.
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.
Christoph Westphal is an American biomedical businessman.
Michelle Dipp is an American scientist, businesswoman, and investor. She is the co-founder and a managing partner at Biospring Partners and serves on the board of Abzena and Kiniciti.
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
HBI-3000 is an experimental drug candidate that is currently in phase II of human clinical trials as an antiarrhythmic agent. Clinical investigation will test the safety and efficacy of HBI-3000 as a treatment for both atrial and ventricular arrhythmias.
Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.
Sir Dennis Barry Gillings is an American-based British billionaire statistician and entrepreneur, the founder and former chairman of Quintiles Transnational, a clinical research company, headquartered in Durham, North Carolina.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a Chinese pharmaceutical company. It is mostly owned by Fosun International.
Laura Elizabeth Niklason is a physician, professor and internationally recognized researcher in vascular and lung tissue engineering. She is the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University and co-founder, chief executive officer and president of Humacyte, a regenerative medicine company developing bioengineered human tissues.
Rachel Elizabeth Haurwitz is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
William H.Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company's interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics and Entos, Inc.. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
Michelle McMurry-Heath is a medical doctor, immunologist, and from June 2020 until October 2022 served as chief executive officer for the Biotechnology Innovation Organization (BIO).
